Sanara MedTech Inc. (SMTI)
USD 29.96
(3.13%)
USD 29.96
(3.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 29.28 Million USD | 51.61% |
| 2022 | 19.31 Million USD | 209.32% |
| 2021 | 6.24 Million USD | 56.66% |
| 2020 | 3.98 Million USD | -15.64% |
| 2019 | 4.72 Million USD | 144.81% |
| 2018 | 1.92 Million USD | -8.76% |
| 2017 | 2.11 Million USD | -18.46% |
| 2016 | 2.59 Million USD | -2.58% |
| 2015 | 2.66 Million USD | 14.6% |
| 2014 | 2.32 Million USD | -32.56% |
| 2013 | 3.44 Million USD | -33.73% |
| 2012 | 5.19 Million USD | -32.41% |
| 2011 | 7.69 Million USD | 96.51% |
| 2010 | 3.91 Million USD | 59.28% |
| 2009 | 2.45 Million USD | 419.61% |
| 2008 | 472.97 Thousand USD | -78.69% |
| 2007 | 2.21 Million USD | 25.59% |
| 2006 | 1.76 Million USD | 95.22% |
| 2005 | 905.27 Thousand USD | 458.02% |
| 2004 | 162.22 Thousand USD | 0.0% |
| 2001 | 3.56 Million USD | 41.53% |
| 2000 | 2.51 Million USD | 37.64% |
| 1999 | 1.82 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 27.9 Million USD | -4.72% |
| 2024 Q2 | 31.98 Million USD | 14.63% |
| 2023 Q2 | 17.31 Million USD | -6.35% |
| 2023 FY | 29.28 Million USD | 51.61% |
| 2023 Q4 | 29.28 Million USD | -6.67% |
| 2023 Q3 | 31.37 Million USD | 81.22% |
| 2023 Q1 | 18.48 Million USD | -4.28% |
| 2022 FY | 19.31 Million USD | 209.32% |
| 2022 Q1 | 5.41 Million USD | -13.23% |
| 2022 Q2 | 11.02 Million USD | 103.53% |
| 2022 Q3 | 16.82 Million USD | 52.61% |
| 2022 Q4 | 19.31 Million USD | 14.78% |
| 2021 FY | 6.24 Million USD | 56.66% |
| 2021 Q1 | 3.54 Million USD | -11.03% |
| 2021 Q2 | 4.12 Million USD | 16.38% |
| 2021 Q4 | 6.24 Million USD | 38.6% |
| 2021 Q3 | 4.5 Million USD | 9.16% |
| 2020 FY | 3.98 Million USD | -15.64% |
| 2020 Q1 | 2.96 Million USD | -37.18% |
| 2020 Q2 | 4.47 Million USD | 50.84% |
| 2020 Q3 | 4.08 Million USD | -8.67% |
| 2020 Q4 | 3.98 Million USD | -2.5% |
| 2019 Q4 | 4.72 Million USD | -24.32% |
| 2019 Q1 | 3.98 Million USD | 106.73% |
| 2019 Q3 | 6.24 Million USD | 36.7% |
| 2019 Q2 | 4.56 Million USD | 14.47% |
| 2019 FY | 4.72 Million USD | 144.81% |
| 2018 Q1 | 479 Thousand USD | -77.36% |
| 2018 Q3 | 2.09 Million USD | 272.88% |
| 2018 Q4 | 1.92 Million USD | -8.02% |
| 2018 FY | 1.92 Million USD | -8.76% |
| 2018 Q2 | 562.72 Thousand USD | 17.48% |
| 2017 Q2 | 2.17 Million USD | -4.8% |
| 2017 Q3 | 2.33 Million USD | 7.6% |
| 2017 FY | 2.11 Million USD | -18.46% |
| 2017 Q1 | 2.28 Million USD | -12.07% |
| 2017 Q4 | 2.11 Million USD | -9.48% |
| 2016 Q1 | 2.4 Million USD | -9.84% |
| 2016 FY | 2.59 Million USD | -2.58% |
| 2016 Q2 | 2.45 Million USD | 2.15% |
| 2016 Q4 | 2.59 Million USD | 3.8% |
| 2016 Q3 | 2.49 Million USD | 1.91% |
| 2015 Q4 | 2.66 Million USD | 2.4% |
| 2015 Q2 | 2.58 Million USD | 16.76% |
| 2015 Q1 | 2.21 Million USD | -4.76% |
| 2015 FY | 2.66 Million USD | 14.6% |
| 2015 Q3 | 2.6 Million USD | 0.63% |
| 2014 FY | 2.32 Million USD | -32.56% |
| 2014 Q2 | 2.35 Million USD | 4.73% |
| 2014 Q1 | 2.24 Million USD | -34.71% |
| 2014 Q4 | 2.32 Million USD | -7.04% |
| 2014 Q3 | 2.49 Million USD | 6.1% |
| 2013 FY | 3.44 Million USD | -33.73% |
| 2013 Q3 | 6.66 Million USD | 22.25% |
| 2013 Q4 | 3.44 Million USD | -48.31% |
| 2013 Q1 | 6.09 Million USD | 17.17% |
| 2013 Q2 | 5.45 Million USD | -10.49% |
| 2012 FY | 5.19 Million USD | -32.41% |
| 2012 Q2 | 5.61 Million USD | -18.6% |
| 2012 Q3 | 6.36 Million USD | 13.38% |
| 2012 Q4 | 5.19 Million USD | -18.31% |
| 2012 Q1 | 6.89 Million USD | -10.36% |
| 2011 Q3 | 2.96 Million USD | -23.53% |
| 2011 Q4 | 7.69 Million USD | 159.51% |
| 2011 FY | 7.69 Million USD | 96.51% |
| 2011 Q2 | 3.87 Million USD | 32.35% |
| 2011 Q1 | 2.92 Million USD | -25.18% |
| 2010 FY | 3.91 Million USD | 59.28% |
| 2010 Q3 | 4.75 Million USD | 12.94% |
| 2010 Q4 | 3.91 Million USD | -17.68% |
| 2010 Q1 | 3.58 Million USD | 45.76% |
| 2010 Q2 | 4.21 Million USD | 17.53% |
| 2009 FY | 2.45 Million USD | 419.61% |
| 2009 Q4 | 2.45 Million USD | 52.97% |
| 2009 Q3 | 1.6 Million USD | 28.64% |
| 2009 Q2 | 1.24 Million USD | 19.48% |
| 2009 Q1 | 1.04 Million USD | 121.02% |
| 2008 Q1 | 1.58 Million USD | -28.74% |
| 2008 Q4 | 472.97 Thousand USD | -70.85% |
| 2008 Q3 | 1.62 Million USD | -6.95% |
| 2008 Q2 | 1.74 Million USD | 10.23% |
| 2008 FY | 472.97 Thousand USD | -78.69% |
| 2007 Q2 | 1.98 Million USD | 2.17% |
| 2007 Q3 | 2.01 Million USD | 1.44% |
| 2007 FY | 2.21 Million USD | 25.59% |
| 2007 Q4 | 2.21 Million USD | 10.19% |
| 2007 Q1 | 1.94 Million USD | 9.96% |
| 2006 Q1 | 1.03 Million USD | 14.79% |
| 2006 Q2 | 1.24 Million USD | 19.49% |
| 2006 Q4 | 1.76 Million USD | 26.36% |
| 2006 Q3 | 1.39 Million USD | 12.64% |
| 2006 FY | 1.76 Million USD | 95.22% |
| 2005 Q3 | 869.47 Thousand USD | 6.6% |
| 2005 Q2 | 815.64 Thousand USD | 52.19% |
| 2005 Q4 | 905.27 Thousand USD | 4.12% |
| 2005 FY | 905.27 Thousand USD | 458.02% |
| 2005 Q1 | 535.92 Thousand USD | 230.36% |
| 2004 Q2 | 639.74 Thousand USD | 4.53% |
| 2004 Q3 | 757.04 Thousand USD | 18.34% |
| 2004 FY | 162.22 Thousand USD | 0.0% |
| 2004 Q4 | 162.22 Thousand USD | -78.57% |
| 2004 Q1 | 612.01 Thousand USD | 0.0% |
| 2002 Q1 | 4.02 Million USD | 13.15% |
| 2001 Q2 | 2.82 Million USD | 7.08% |
| 2001 Q3 | 3.3 Million USD | 17.23% |
| 2001 Q4 | 3.56 Million USD | 7.64% |
| 2001 Q1 | 2.63 Million USD | 4.75% |
| 2001 FY | 3.56 Million USD | 41.53% |
| 2000 Q4 | 2.51 Million USD | 12.19% |
| 2000 Q1 | 1.95 Million USD | 0.0% |
| 2000 Q3 | 2.24 Million USD | 2.66% |
| 2000 FY | 2.51 Million USD | 37.64% |
| 2000 Q2 | 2.18 Million USD | 11.95% |
| 1999 FY | 1.82 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | 76.869% |
| AngioDynamics, Inc. | 112.08 Million USD | 73.874% |
| AtriCure, Inc. | 147.76 Million USD | 80.182% |
| Avinger, Inc. | 19.97 Million USD | -46.621% |
| Azenta, Inc. | 351.22 Million USD | 91.662% |
| BioLife Solutions, Inc. | 75.05 Million USD | 60.982% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 99.287% |
| Daxor Corporation | 858.75 Thousand USD | -3309.94% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | -79.519% |
| Femasys Inc. | 9.4 Million USD | -211.415% |
| GlucoTrack, Inc. | 1.7 Million USD | -1614.469% |
| Harvard Bioscience, Inc. | 64.29 Million USD | 54.453% |
| Hologic, Inc. | 4.02 Billion USD | 99.273% |
| ICU Medical, Inc. | 2.25 Billion USD | 98.701% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 98.568% |
| KORU Medical Systems, Inc. | 8.1 Million USD | -261.199% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | 40.089% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -4337.268% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -4337.268% |
| Masimo Corporation | 1.67 Billion USD | 98.254% |
| Microbot Medical Inc. | 3.82 Million USD | -665.372% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | -16.771% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 97.393% |
| Nephros, Inc. | 3.5 Million USD | -735.944% |
| NovoCure Limited | 783.63 Million USD | 96.263% |
| NEXGEL, Inc. | 4.78 Million USD | -511.467% |
| NEXGEL, Inc. | 4.78 Million USD | -511.467% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | 66.131% |
| OraSure Technologies, Inc. | 52.17 Million USD | 43.874% |
| Pro-Dex, Inc. | 23.34 Million USD | -25.447% |
| Pulse Biosciences, Inc. | 16.44 Million USD | -78.078% |
| Predictive Oncology Inc. | 6.14 Million USD | -376.5% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | -327.817% |
| QuidelOrtho Corporation | 3.55 Billion USD | 99.177% |
| Repligen Corporation | 853.2 Million USD | 96.568% |
| STAAR Surgical Company | 102.73 Million USD | 71.497% |
| Sharps Technology, Inc. | 3.85 Million USD | -659.618% |
| Utah Medical Products, Inc. | 7.14 Million USD | -309.841% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.282% |
| Jin Medical International Ltd. | 8.92 Million USD | -228.126% |